XLV - Health Care Select Sector SPDR ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
-0.64 (-0.69%)
At close: 4:00PM EDT

91.27 -0.67 (-0.73%)
Pre-Market: 7:48AM EDT

Stock chart is not supported by your current browser
Previous Close92.58
Bid90.15 x 2200
Ask91.46 x 1000
Day's Range91.58 - 92.58
52 Week Range78.74 - 96.06
Avg. Volume10,639,143
Net Assets19.23B
PE Ratio (TTM)N/A
YTD Return7.49%
Beta (3Y Monthly)0.90
Expense Ratio (net)0.13%
Inception Date1998-12-16
Trade prices are not sourced from all markets
  • One of Wall Street's biggest bulls says a rally is coming and it may even top his expectations
    CNBC Videos3 days ago

    One of Wall Street's biggest bulls says a rally is coming and it may even top his expectations

    Julian Emanuel, BTIG, on the approaching rally and why financials is a top sector. With CNBC's Joe Kernen and the Fast Money traders, Tim Seymour, Brian Kelly, Steve Grasso and Guy Adami.

  • No recession coming soon but no growth either says advisor
    Yahoo Finance Video7 days ago

    No recession coming soon but no growth either says advisor

    Ron Weiner of RDM Financial Group at HighTower gives his outlook on the markets and the economy. He talks with Yahoo Finance's Julie Hyman and Adam Shapiro.

  • Don't chase tech here, recommends top strategist Dan Suzuki
    CNBC Videos10 days ago

    Don't chase tech here, recommends top strategist Dan Suzuki

    Dan Suzuki, Richard Bernstein Advisors, says investors shouldn't chase tech, and recommends heath care and staples. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Brian Kelly and Steve Grasso.

  • Top strategist says new highs are in sight
    CNBC Videos16 days ago

    Top strategist says new highs are in sight

    Keith Parker, UBS, says new highs are in sight. Bargain buys, with CNBC's Scott Wapner and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Mark Tepper.

  • MarketWatchyesterday

    Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million

    Pfizer Inc. said Wednesday it has paid 45 million euro, or the equivalent of $51 million to acquire a 15% equity stake in privately held gene therapy company Vivet Therapeutics, and has acquired an option to buy the rest of Vivet shares for EUR560 million ($635.8 million). Pfizer's stock rose 0.2% in premarket trade. Pfizer and Vivet will collaborate on developing VTX-801, Vivet's treatment for Wilson disease, a life-threatening liver disorder of impaired copper transport. Under terms of the deal, Pfizer can exercise its option to buy 100% of Vivet after the company's delivery of certain data from the phase 1/2 trial for VTX-801. Monika Vnuk, vice president of worldwide business development at Pfizer, will join Vivet's board of directors. Pfizer's stock has gained 16.4% over the past 12 months through Tuesday, while the Dow Jones Industrial Average has tacked on 4.7%.

  • MarketWatch6 days ago

    BioScrip's stock soars after merger deal with Option Care, owned by Walgreens and Madison Dearborn

    Shares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.

  • MarketWatch7 days ago

    J&J's stock falls after reports company ordered to pay $29 million to woman dying of cancer

    Shares of Johnson & Johnson dropped 1.7% in premarket trade Thursday, after reports that the health care and consumer products giant was ordered by a California court to pay $29 million to a woman dying of cancer. The court determined J&J was liable in the suit, which claimed the cancer--mesothelioma--was caused by the asbestos in the company's talcum powder, the reports said. Last month, J&J disclosed that it received subpoenas from the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the SEC to produce documents regarding liability suits related to the safety of its baby powder. The stock has gained 5.4% over the past 12 months, while the SPDR Health Care Select Sector ETF has tacked on 7.3% and the Dow Jones Industrial Average has advanced 3.8%.

  • ETF Trends8 days ago

    Bullish on CVS? Look to Hot Healthcare ETFs

    Healthcare stocks and sector-related ETFs were among the best performing segments of the markets Wednesday, with CVS Health Corp (NYSE: CVS) rallying on a bullish call out from Bernstein analysts. Among ...

  • Why Eli Lilly Stock Fell Yesterday
    Market Realist9 days ago

    Why Eli Lilly Stock Fell Yesterday

    Why Eli Lilly Stock Fell YesterdayStock price movements Yesterday, Eli Lilly (LLY) closed at $123.50, 2.53% lower than its previous closing price, 65.75% higher than its 52-week low of $74.51, and 5.37% below its 52-week high of $130.51. The

  • Job Growth Almost Halts in US: Sector ETFs in Focus
    Zacks10 days ago

    Job Growth Almost Halts in US: Sector ETFs in Focus

    These sector ETFs can gain/lose after the lackluster U.S. jobs report for the month of February.

  • ETF Trends15 days ago

    Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook

    Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after FDA Commissioner Scott Gottlieb unexpectedly resigned, ...

  • MarketWatch17 days ago

    Health care ETF's 'bearish engulfing' chart pattern warns of an end to the recent uptrend

    The intraday U-turn in the SPDR Health Care Select Sector ETF has produced a "bearish engulfing" reversal chart pattern, which many technicians would say warns that the 2-month uptrend in the sector has ended. The ETF (XLV) opened $93.28, above the Friday's close of $92.95, then rose to a 3-month high of $93.45 in intraday trade before reversing course to close at $91.69, or below Friday's open of $92.22. Candlestick-chart followers believe this pattern suggests that after bears took the bulls' best shot, they launched a successful counterattack that have left bulls retreating. The XLV's decliners Monday were led by shares of managed care companies WellCare Health Plans Inc. , Anthem Inc. and Humana Inc. . Among some downside levels to watch are the 200-day moving average, which currently extends to $89.23, and the 61.8% Fibonacci retracement of the rally off the Dec. 24 closing low to Friday's high, which comes in at $85.38. The XLV has gained 6.0% year to date while the S&P 500 has run up 13.0%.

  • Benzinga18 days ago

    Best Sector ETFs For March: Last Year's Laggards Have Their Day

    Some of last year's laggard sectors and the related exchange traded funds are already rebounding, but if historical trends hold firm, March could bring more of the same. Using the sector SPDR exchange traded funds as the barometers, none of the original nine members of the sector SPDR suite average March losses. Going back to 1999, the first full year of trading for the sector SPDR ETFs, the best-performing fund in that group in the month of March is the Energy Select Sector SPDR (NYSE: XLE).

  • What Wall Street Recommends for Amarin after Q4 2018 Results
    Market Realist20 days ago

    What Wall Street Recommends for Amarin after Q4 2018 Results

    Amarin Stock: The Outlook after the Q4 2018 ResultsShare price movements On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of

  • MarketWatch21 days ago

    Medicare for All Act clips managed care and provider stocks for a second day

    Shares of managed care and provider companies slumped for a second-straight session Thursday, in the wake of the introduction of the Medicare-for-All Act to Congress on Wednesday. The bill, introduced by Reps. Pramila Jayapal of Washington, Debbie Dingell of Michigan and others looks for a quick 2-year transition out of employer-sponsored coverage into single-payor Medicare run by the government. Analyst Gary Taylor at J.P. Morgan said he doesn't expect a quick snap-back rally in the managed care and provider stocks this week, but doesn't believe they could rally off lows by summer. He then expects that rally to fade into the second half of the year, as Democratic Presidential debates begin in the fall. Shares of UnitedHealth Group Inc. lost 3% to pace the Dow Jones Industrial Average's decliners, after losing 4.9% on Wednesday; Cigna Corp. sank 3.4%, after falling 4.0% on Wednesday; Humana Inc. shed 1.0% after dropping 4.8% the day before; WellCare Health Plans Inc. slid 3.3% after giving up 3.9% Wednesday; and Anthem Inc. declined 1.8% after losing 3.6% on Wednesday. In comparison, the Dow slipped 0.2% after easing 0.3% the day before.

  • MarketWatch21 days ago

    Celgene's stock tumbles after Bristol-Myers shareholders oppose the buyout deal

    Shares of Celgene Corp. tumbled 8.0% in afternoon trade Thursday, after Bristol-Myers Squibb Co. shareholder Starboard Value L.P. said it plans to vote all of its shares against Bristol-Myers' proposed acquisition of Celgene. Starboard said given a history of underperformance, Bristol-Myers' management hasn't earned the right to execute a "bet the company" deal. "We are writing today as we believe that Bristol-Myers is deeply undervalued and the recent announcement of the company's proposed acquisition of [Celgene] is poorly conceived and ill-advised," wrote Jeffrey Smith, a managing member of Starboard, in a letter to shareholders. The companies said the termination fee on the deal is $2.2 billion. Starboard's letter comes a day after shareholder Wellington Management Co., which owns 8.3% of Bristol-Myers shares outstanding, said it opposed the deal. Bristol-Myers responded by saying it believes buying Celgene is the "natural next step" in the evolution of the company, as it will create "a premier biopharma company" that delivers "substantial benefits" to shareholders. Bristol-Myers stock rose 2.4% on Thursday, but has lost 21% over the past 12 months, while the SPDR Health Care Select Sector ETF has rallied 9.3% and the S&P 500 has tacked on 2.8%.

  • What Analysts Are Recommending for Teva Pharmaceutical This Month
    Market Realistlast month

    What Analysts Are Recommending for Teva Pharmaceutical This Month

    Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower

  • Benzingalast month

    State Of The Union Fallout For Trade War, Pharma And Infrastructure Stocks

    President Donald Trump delivered his highly anticipated State of the Union address Tuesday night. U.S. investors were hoping for a positive update on trade negotiations with China. The ongoing trade war rattled the market in the fourth quarter, and several major U.S. companies have blamed China for earnings and guidance misses.

  • MarketWatchlast month

    Humana earnings and revenue beat expectations

    Humana Inc. reported Wednesday fourth-quarter earnings and revenue that beat expectations, helped by lower inpatient medical utilization, which was partially offset by higher outpatient spending. The health care company's stock was still inactive in premarket trade. Net income was $436 million, or $2.58 a share, compared with $490 million, or $1.29 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $2.65, above the FactSet consensus of $2.53. Revenue rose to $14.17 billion from $13.19 billion, beating the FactSet consensus of $13.94 billion. For 2019, the company expects adjusted EPS of $17.00 to $17.50, compared with the FactSet consensus of $17.48. Humana shares have dropped 8.6% over the past three months, while the SPDR Health Care Select Sector ETF has slipped 0.2% and the S&P 500 has eased 0.6%.

  • 5 ETFs to Tap for February
    Zackslast month

    5 ETFs to Tap for February

    These five ETFs could be worth investing in.

  • What Are Analysts Recommending for Merck after Q4 2018 Results?
    Market Realistlast month

    What Are Analysts Recommending for Merck after Q4 2018 Results?

    Is Merck an Attractive Buy after Q4 2018 Results?Stock price movementsOn February 1, Merck (MRK) closed at $76.45, 2.67% higher than its previous closing price, 44.71% higher than its 52-week low of $52.83, and 4.66% below its 52-week high of

  • 7 Sector ETFs to Buy for 2019 and Beyond
    InvestorPlace2 months ago

    7 Sector ETFs to Buy for 2019 and Beyond

    [Editor's note: This article was previously published in December 2017. It has since been updated and republished to reflect new fund information.] The best exchange-traded funds (ETF) that you should buy will likely be funds that concentrate their holdings in sectors that can beat the broad market indices. As is the case in almost every calendar year, some of the best ETFs will be top funds from the previous year that continue their momentum into the new year, while others will be recent laggards that make a big turnaround. InvestorPlace - Stock Market News, Stock Advice & Trading Tips But picking the best ETFs for an entire year can be challenging, especially because there are always scenarios that play out that no one could have predicted accurately in advance. Therefore, the smart bets for the top ETFs will be a diverse list of funds that combine the best momentum plays based upon what we know now along with some contrarian bets that go against the herd consensus. * 10 High-Yield Monthly Dividend Stocks So, with that backdrop, here are the seven of the best sector funds that can lead the market … ### iShares Edge MSCI USA Momentum Factor (MTUM) Expenses: 0.15%, or $15 annually for every $10,000 invested Momentum will be a major theme of markets and the best way to capture the trend is iShares Edge MSCI USA Momentum Factor (NYSEARCA:MTUM). Although this ETF does not focus on one single sector, it's a great way to gain exposure to momentum stocks that will inevitably come from the leading sectors, without having to identify them yourself. MTUM offers shareholders exposure to momentum in the market by passively tracking the performance of an index of large- and mid-cap stocks with high relative momentum characteristics. For example, top holdings that met this criteria as of this writing were JPMorgan Chase & Co. (NYSE:JPM), Microsoft Corporation (NASDAQ:MSFT), and Bank of America Corp (NYSE:BAC). ### Financial Select Sector SPDR Fund (XLF) Expenses: 0.13% With rising interest rates and a resilient stock market, financial stocks should maintain leadership, which makes ETFs like the Financial Select Sector SPDR Fund (NYSEARCA:XLF) a smart fund to hold. Higher rates generally translate into wider spreads for financial institutions that lend money, and a healthy stock market means higher profits for the big brokerage firms and other large financial companies involved in capital markets. * 10 Smart Money Stocks to Buy for the Rest of the Year XLF, the oldest financial sector ETF, tracks the Financial Select Sector Index, which focuses primarily on large U.S. stocks like Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B), JPM and BAC. ### Energy Select Sector SPDR (XLE) Expenses: 0.13% Although energy was a lagging sector for much of the past few years, signs of life emerged and this momentum has legs to move into 2019, which would benefit top energy ETFs like Energy Select Sector SPDR (NYSEARCA:XLE). XLE tracks the Energy Select Sector Index, which consists of 25 stocks of companies in the oil and gas industries, as well as energy equipment and services. This means shareholders of XLE get a healthy dose of energy sector stocks like Exxon Mobil Corporation (NYSE:XOM), Chevron Corporation (NYSE:CVX) and Schlumberger Limited. (NYSE:SLB). ### PowerShares S&P SmallCap Information Technology (PSCT) Expenses: 0.29% Technology promises to continue as a market leader this year and funds like PowerShares S&P SmallCap Information Technology (NYSEARCA:PSCT) could be smart bets in the tech sector. After a period of small-caps lagging large-caps, the trend started to turn around, which could make PSCT a smart momentum growth bet. PSCT passively tracks the S&P SmallCap 600 Capped Information Technology Index, which is an S&P SmallCap 600 subset that consists of small-cap stocks of companies that provide information technology-related products and services. * 7 Blue-Chip Stocks That Could Lead the Market Higher This means shareholders get exposure to small info-tech names like MKS Instruments, Inc. (NASDAQ:MKSI), Lumentum Holdings Inc (NASDAQ:LITE) and Stamps.com Inc. (NASDAQ:STMP). ### Health Care SPDR (ETF) (XLV) Expenses: 0.13% Health sector ETFs have taken a hit recently, but they have returned to market leadership, which makes now a good time to consider holding funds like the Health Care SPDR (ETF) (NYSEARCA:XLV). The health sector can work as a long-term growth play or a short- to intermediate-term defensive play, which makes health stocks like XLV top holdings Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE) and UnitedHealth Group Inc (NYSE:UNH) a good idea to hold in almost any portfolio. XLV has a good balance of health sector stocks, which means it won't be as volatile as some of the health sector ETFs that are more concentrated in sub-sectors of health. This diversification can also serve as added insulation amid health legislation talks in Congress. ### Vanguard Utilities ETF (VPU) Expenses: 0.10% The utilities sector has quietly remained just behind the major market indices for performance the past few years, and it has recently picked up momentum. Combined with their defensive qualities, utilities ETFs look good for 2019. The Vanguard Utilities ETF (NYSEARCA:VPU) passively tracks an index that consists of 75 quality U.S. utilities stocks like NextEra Energy Inc (NYSE:NEE), Duke Energy Corp (NYSE:DUK) and Southern Co (NYSE:SO). * 5 Dividend Stocks to Help You Through the Market's Mayhem The defensive nature of utilities will show its value once the stock market sees another major correction, which remains a real possibility in 2019. ### Consumer Staples Select Sect. SPDR (ETF) (XLP) Expenses: 0.13% Diversification will likely be a major theme in 2019 and a smart move for that purpose is to hold a defensive stock ETF like the Consumer Staples Select Sect. SPDR (ETF) (NYSEARCA:XLP). If stocks continue their climb, this year will see the nine-year anniversary for the bull market, which is getting old by historical standards. Therefore, now is arguably one of the best times in a decade to begin shifting portfolio holdings to a more defensive posture. XLP holds a wide variety of defensive stocks like Procter & Gamble Co (NYSE:PG), Philip Morris International Inc. (NYSE:PM), and The Coca-Cola Co (NYSE:KO). As of this writing, Kent Thune did not personally hold a position in any of the aforementioned securities. However, he holds XLE, XLV and XLP in some client accounts. Under no circumstances does this information represent a recommendation to buy or sell securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Machine-Learning Stocks to Buy for a Smarter Portfolio * 10 Stocks to Sell in February * 10 Triple-A Stocks to Buy in February Compare Brokers The post 7 Sector ETFs to Buy for 2019 and Beyond appeared first on InvestorPlace.

  • Pfizer: Analysts’ Recommendations after Its Q4 Results
    Market Realist2 months ago

    Pfizer: Analysts’ Recommendations after Its Q4 Results

    Is Pfizer an Attractive Buy after Its Q4 Results?Share price movementsOn January 29, Pfizer (PFE) released its fourth-quarter and fiscal 2018 results. The stock closed at $40.77, which is 3.14% higher than its previous closing price. The company